Advertisement
Advertisement
U.S. Markets open in 5 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Roivant Sciences Ltd. (87S.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
4.7000+0.0700 (+1.51%)
As of 09:15AM CET. Market open.
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

    Expected cash runway extended into the second half of calendar year 2025First major PBM/payer contract signed for VTAMA, effective October 1Over 54,000 VTAMA prescriptions written by approximately 6,400 prescribers since launch show strong demand, with fiscal Q2 2022 net product revenue of $5.0 millionUnveiled IMVT-1402, a next generation anti-FcRn which showed deep IgG lowering similar to batoclimab with no or minimal impact observed on albumin and LDL (low-density lipoprotein) levels in animal

  • GlobeNewswire

    Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

    NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32). AFVT-2101 is a tetravalent, bispecific Innate Cell Engager (ICE®) that bridges folate receptor alpha (FRα) on tumo

  • GlobeNewswire

    Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

    BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary public offering of 30,000,000 common shares of Roivant, consisting of 20,000,000 common shares offered by Roivant and 10,000,000 common shares offered by the selling shareholders at a price to the public of $5

Advertisement
Advertisement